Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.

Summary

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women.

Timeline

Start

2024-10-14

Primary completion

2025-04-17

Completion

2025-07-29

Outcome

Met primary endpoint

release “GS1-144 reduced both the frequency and severity of moderate-to-severe VMS in Chinese postmenopausal women.” genscigroup.com ↗

Drugs

Indications